BrightPath Biotherapeutics

4594.TTSE GROWTHPharmaceutical

Filed as BrightPath Biotherapeutics Co., Ltd (2022-06–2026-06)

Key numbers · FY ended 2018-03

Revenue¥354m-33.1% YoY Operating income−¥1.6bn—Net income (owners)−¥1.6bn—Total assets¥7.2bn+33.8% YoY EPS (basic)¥-41.25-26.0% YoY

Full financial history and reports →

Stock price4594 · View chart ↗

Open the price chart on TradingView.

Latest filings

Wed, Oct 7 · JST1 filing

15:515% STAKEBrightPath Biotherapeutics · PhillipCapital Japan Ltd. · 19.90%new 19.90%

Thu, Feb 19 · JST1 filing

09:005% STAKEBrightPath Biotherapeutics · Phillip Securities Japan, Ltd. · 6.29% → 4.88%−1.41pp

Thu, Jan 29 · JST1 filing

09:385% STAKEBrightPath Biotherapeutics · Phillip Securities Japan, Ltd. · 7.29% → 6.29%−1.00pp

Wed, Jan 21 · JST1 filing

13:255% STAKEBrightPath Biotherapeutics · Phillip Securities Japan, Ltd. · 7.29%new 7.29%

Tue, Jan 20 · JST1 filing

13:415% STAKEBrightPath Biotherapeutics · Phillip Securities Japan, Ltd. · 18.94% → 9.24%−9.70pp

All filings →

Major holders (5%+) · 0

Holder	Stake	Change	Filed

No holder currently reports 5% or more.

Each holder's own ratio from its most recent large-shareholding report.